Statistics for Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up
Total visits
views | |
---|---|
Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up | 1 |
Total visits per month
views | |
---|---|
October 2023 | 0 |
November 2023 | 0 |
December 2023 | 0 |
January 2024 | 0 |
February 2024 | 0 |
March 2024 | 0 |
April 2024 | 0 |